echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Hengrui Pharmaceuticals Carrelizumab Approved for First-line Treatment of Nasopharyngeal Carcinoma

    Hengrui Pharmaceuticals Carrelizumab Approved for First-line Treatment of Nasopharyngeal Carcinoma

    • Last Update: 2021-06-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Hengrui Medicine Carrelizumab was approved as the first-line treatment for nasopharyngeal carcinoma, which is its sixth indication
    Hengrui Pharmaceuticals Karelizumab was approved for the first-line treatment of nasopharyngeal carcinoma, its sixth indication Hengrui Pharmaceuticals Karelizumab was approved for the first-line treatment of nasopharyngeal carcinoma, its sixth indication

    On June 10, Hengrui Medicine (600276.
    SH) announced that its self-developed PD-1 inhibitor carrelizumab (trade name: Erica) was officially approved and issued by the National Medical Products Administration.
    The "Drug Registration Certificate" approves carrelizumab combined with cisplatin and gemcitabine for the first-line treatment of patients with locally recurring or metastatic nasopharyngeal carcinoma
    .

    This indication is the first approved first-line nasopharyngeal carcinoma indication in the world, and it is also approved after Hodgkin’s lymphoma, liver cancer, lung cancer, esophageal squamous cell carcinoma, second-line nasopharyngeal carcinoma and above.
    The sixth indication
    .


    Up to now, carrelizumab is still the domestic PD-1 inhibitor with the most approved indications


    According to Hengrui Medicine, the approval of the new indication of Carrelizumab is based on the CAPTAIN-1ST study
    .


    CAPTAIN-1 study


    Hengrui Medicine stated that the above research results have been presented orally at the 2021 American Society of Clinical Oncology (ASCO) annual meeting, and the full text has also been accepted by The Lancet Oncology and will be released in the near future.

    .

    Four domestic PD-1s have been approved, and the continuous expansion of their indications has become the focus of competition among companies
    .


    In terms of nasopharyngeal cancer, in addition to Hengrui Medicine’s carrelizumab, Junshi Bio (688180.


    During the annual meeting of the American Society of Clinical Oncology (ASCO), a global multicenter, randomized, double-blind, placebo-controlled phase III clinical study of teriprizumab combined with chemotherapy in the first-line treatment of recurrent/metastatic nasopharyngeal carcinoma (JUPITER-02) The latest results are also announced, showing that compared with chemotherapy alone, terreplimumab combined with gemcitabine chemotherapy can achieve better progression-free survival (PFS) and higher objective remission in the first-line treatment of recurrent/metastatic nasopharyngeal carcinoma Rate (ORR) and longer duration of remission (DOR), and has good safety and tolerability
    .

    At the just-concluded 2021ASCO annual meeting, Hengrui Medicine and Junshi Bio-PD-1 inhibitors both announced numerous research progress
    .


    According to Hengrui Medicine, Carrelizumab has been selected in 38 studies, covering 11 cancer types including breast cancer, gastrointestinal tumors, lung cancer, and pancreatic cancer; Junshi Biology official website shows that during the ASCO annual meeting, there are Ten phase II studies in the adjuvant/neo-adjuvant/perioperative treatment of non-small cell lung cancer, esophageal cancer, gastric cancer, mucosal melanoma and other fields with teriprizumab have been unveiled


    It is foreseeable that in the future, domestic PD-1 inhibitors will have more intense competition in indications


    Admiral
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.